Zevra Therapeutics Inc (ZVRA) financials
Zevra Therapeutics revenue and earnings by year
Zevra Therapeutics's revenue was $106 million in the fiscal year to December 31, 2025, up 350.9% from the year before. Net income was $83.2 million, 78.2% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 42.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 106 | 24 | 27 | 10 | 29 | 13 | 13 |
| Revenue growth | 350.9% | -14.0% | 170.3% | -64.5% | 115.6% | 3.5% | — |
| Gross profit | 90 | 16 | 25 | 10 | 27 | — | — |
| Gross margin | 84.5% | 68.6% | 92.1% | 97.8% | 92.8% | — | — |
| Operating income | -63 | -87 | -50 | -43 | 8 | -6 | -20 |
| Operating margin | -59.1% | -368.5% | -180.6% | -418.9% | 27.0% | -42.2% | -158.4% |
| Net income | 83 | -106 | -46 | -27 | -9 | -13 | -25 |
| Net margin | 78.2% | -446.9% | -167.7% | -263.5% | -29.9% | -96.0% | -191.0% |
| Diluted EPS | $1.35 | — | — | — | -$2.11 | -$3.21 | — |
| Free cash flow | -2 | -70 | -34 | -19 | 10 | -2 | -24 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ZVRA in Markets.
See also: ZVRA valuation and P/E history · ZVRA returns
No forecast, no recommendation. This page describes Zevra Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.